BAVA:VIE
Bavarian Nordic A/S
32,08 €
arrow_upward
+1,84%(+0,58) 1 d
12 oct, 13:00:35 GMT+2 · EUR
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de BAVA...
Abrir
31,48 €
Alto
32,10 €
Bajo
31,48 €
Cap. burs.
2815,57 M
Vol. medio
17,00
Volumen
0,00
Máximo en 52 sem.
32,47 €
Mínimo en 52 sem.
22,96 €
N.º de empleados
2 mil
Abrir
31,48 €
Alto
32,10 €
Bajo
31,48 €
Cap. burs.
2815,57 M
Vol. medio
17,00
Volumen
0,00
Máximo en 52 sem.
32,47 €
Mínimo en 52 sem.
22,96 €
N.º de empleados
2 mil
Noticias
De fuentes web y partners de noticias
El Ecosistema Startup
·
hace 34 minutos
S&P 500: 4 años alcistas y las 10 acciones más rentables
Investing.com España
·
hace 27 minutos
Dow Jones, Nasdaq, S&P 500: Los mercados se preparan para el IPC y el inicio de resultados del tercer trimestre
Perfil
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Acerca de Bavarian Nordic A/S